Novartis AG
USE OF CANAKINUMAB
Last updated:
Abstract:
Use of an IL-1.beta. inhibitor such as canakinumab for the treatment and/or prevention of osteoarthritis and complications related thereto.
Status:
Application
Type:
Utility
Filling date:
24 Aug 2018
Issue date:
2 Dec 2021